E.Mohammadi a, M. Dastjerdi a,b, A. Jalali a, S. Akbari a,b,c , A. Akbari c
aNanoSciTec GmbH, Hermann Weinhauser str. 67, Munich, 81867, Germany
b BioMedEx GmbH, weyringerg 37 Stiege 1, 1040, Wein, Austria
c GreenNanoTech Kft, Westend Business Center, 22-24 Váci street, Budapest, 1132, Hungary
Abstract
Colorectal cancer (CRC) remains a major global health challenge as the third most common cancer worldwide. Survival relies heavily on early diagnosis and treatment before progression to metastasis. Employing nanotechnology for targeted drug delivery shows promise to enhance therapeutic efficacy and tolerability in CRC. Diverse nanoparticle platforms offer unique advantages as CRC drug carriers with tunable properties like improved pharmacokinetics, stability, sustained release, and tumor cell uptake through endocytosis or transcytosis. Key platforms highlighted include liposomes, polymeric micelles, solid lipid nanoparticles, nanodiscs, cubosomes, and polysaccharide particles. In vivo testing is warranted to translate multiparameter optimized carrier designs to clinical applications. Simulations help predict carrier localization, biodistribution, controlled release, and optimal formulations. Overall, nanomedicine promises more targeted therapeutic delivery to improve survival for CRC patients, especially those with advanced or metastatic disease. However, realizing this potential requires additional pharmacodynamic studies alongside mechanistic clarification and carrier optimization to progress designs to clinical evaluation. Advancing personalized, targeted nanotechnology-enabled treatment options remains imperative.
Keywords: Nanoparticles, Drug delivery, Colorectal cancer, Experimental models, Bioprocess simulation, Manufacturing, Simulation software
© Article info: Accepted by: 25 January 2024, Published by: 13 February 2024.
Doi Number: https://doi.org/10.52319/j.nanoscitec.2023.27
